India’s Zydus joins fight against novel coronavirus

Ahmedabad-based Zydus Cadila, a part of Cadila Healthcare, has launched an accelerated research program…To continue reading The Pharma Letter please login,  subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Anti-viralsBiotechnologyChinaCoronavirusFocus OnIndiaPublic healthResearchVaccinesZydus Cadila Become a Subscriber What you get Unlimited access…

Become a Subscriber

What you get

Unlimited access to The Pharma Letter site for a whole year

Only £77 per month or £820 per year


  • No-limits access to our site with up-to-the minute news
  • Personalised news and email alerts
  • Online discussion forums and Q&A section
  • RSS news feeds that you can add to your favourite reader, or website
  • Daily news email alert, with the breaking news stories and news roundup

Click here to subscribe

“Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed”

Nigel Brooksby, Chairman, Sanofi aventis UK Ltd

Read More